NGM Biopharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
NGM Biopharmaceuticals has a total shareholder equity of $148.6M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $168.9M and $20.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$144.19m |
| Equity | US$148.64m |
| Total liabilities | US$20.23m |
| Total assets | US$168.87m |
Recent financial health updates
We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate
Oct 05
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky
Jun 27We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully
Dec 20Recent updates
What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You
Dec 19We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate
Oct 05Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates
Aug 09Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky
Jun 27NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't
Apr 17We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully
Dec 20NGM Biopharma sinks ~72% after phase 2 trial of its eye degeneration treatment fails
Oct 17NGM Biopharmaceuticals appoints CFO Siobhan Nolan Mangini to the additional role of President
Jun 30NGM Biopharmaceuticals: Eye Disorder Data Due Second Half Of 2022
Jun 21Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth
Jun 15Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week
May 09NGM Biopharmaceuticals: How They Changed A Dead End To A Crossroad
Apr 26Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth
Feb 21We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely
Nov 08Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth
Jul 09NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Mar 06Financial Position Analysis
Short Term Liabilities: NGM's short term assets ($156.4M) exceed its short term liabilities ($20.1M).
Long Term Liabilities: NGM's short term assets ($156.4M) exceed its long term liabilities ($149.0K).
Debt to Equity History and Analysis
Debt Level: NGM is debt free.
Reducing Debt: NGM has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NGM has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: NGM has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 32.7% each year.